Arcutis Biotherapeutics, Inc.
NASDAQ:ARQTBiotechnology
-$0.51 today
- Market cap
- $3.49B
- Beta
- 1.52
- P/E (TTM)
- -1400.0
- EPS (TTM)
- -$0.02
Volume 0.84M
Average 1.61M
ARQT EBITDA Margin
EBITDA as a percentage of revenue.
Arcutis Biotherapeutics, Inc.NASDAQ: ARQT
EBITDA Margin · Q2 FY2026 · quarter ended Jun 2026
EBITDA Margin widens to 13.2%
EBITDA Margin was 13.2% in Q2 FY2026, up 27.9 pp from a year earlier. On a trailing-twelve-month basis it was 9.4%, up 35.4 pp year over year. Over 3 fiscal years it widened by 8000.3 pp.
Context
- EBITDA Margin widened in 3 of the last 3 fiscal years.
- FY2025 was the highest level in the 4 fiscal years shown.
What to watch
Whether EBITDA Margin reaches the consensus estimate from 6 analysts of 19.1% for the fiscal year ending Dec 2026, up from 0.5% in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- 13.2%+19.2 pp QoQ
- Last fiscal yearDec 2025
- 0.5%+56.3 pp YoY
- LTMJun 2026
- 9.4%+35.4 pp YoY
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- 0.5%
- Year-over-year change
- +56.3pp
| Period | Period end | EBITDA Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 0.5% | +56.3pp |
| FY2024 | 2024-12-31 | -55.8% | +327.7pp |
| FY2023 | 2023-12-31 | -383.5% | +7616.3pp |
| FY2022 | 2022-12-31 | -7999.8% | — |
| FY2021 | 2021-12-31 | — | — |
EBITDA Margin vs competitors
How ARQT compares with its peers on the latest reported figures
- ARQT's LTM Jun 2026 EBITDA Margin of 9.4% is the highest of the 4 companies compared; the peer median is -746.2%.
- Its year-over-year change of +35.4 pp is the 2nd highest of 3, against a peer median of -218.6 pp.
- Over three fiscal years its change of +8000.3 pp compares with a peer median of -87.4 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Jun 2026 | 9.4% | +35.4 pp | +8000.3 pp | |
| LTM Mar 2026 | -10.7% | +104.7 pp | +365.5 pp | |
EVMNEvommune, Inc. | LTM Mar 2026 | -746.2% | — | — |
| LTM Mar 2026 | -843.9% | -542.0 pp | -540.2 pp | |
TTRXTurn Therapeutics Inc. | FY2025 | — | — | — |
| FY2025 | — | — | — | |
| Peer median (excluding ARQT) | -746.2% | -218.6 pp | -87.4 pp | |
Competitors are the stored peer set for ARQT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 3.69M | 59.61M | 196.54M | 376.07M |
| Cost of Revenue | 763K | 754K | 4.99M | 19.13M | 36.7M |
| Gross Profit | (763K) | 2.93M | 54.62M | 177.41M | 339.38M |
| Gross Margin | — | 79.5% | 91.6% | 90.3% | 90.2% |
| Research & Development | 145.56M | 182.44M | 110.58M | 76.42M | 77.05M |
| Selling, General & Admin | 60.97M | 122.12M | 185.15M | 229.39M | 274.55M |
| Operating Expenses | 205.77M | 304.56M | 295.72M | 305.81M | 351.6M |
| Depreciation & Amortization | 454K | 934K | 750K | 2.6M | 4.67M |
| EBITDA | (205.9M) | (294.87M) | (228.57M) | (109.63M) | 1.78M |
| EBITDA Margin | — | -7999.8% | -383.5% | -55.8% | 0.5% |
| Operating Income | (206.53M) | (301.63M) | (241.1M) | (128.4M) | (12.23M) |
| Operating Margin | — | -8183.0% | -404.5% | -65.3% | -3.3% |
| Interest Income | 173K | 0 | 0 | 0 | 0 |
| Interest Expense | 0 | 15.65M | 29.71M | 27.17M | 12.08M |
| Other Income / Expenses | 173K | (9.83M) | (17.93M) | (11M) | (2.74M) |
| Income Before Tax | (206.36M) | (311.46M) | (259.03M) | (139.39M) | (14.97M) |
| Pre-Tax Margin | — | -8449.8% | -434.6% | -70.9% | -4.0% |
| Income Tax Expense | 0 | 0 | 3.11M | 647K | 1.17M |
| Net Income | (206.36M) | (311.46M) | (262.14M) | (140.04M) | (16.14M) |
| Net Margin | — | -8449.8% | -439.8% | -71.3% | -4.3% |
| EPS (Basic) | (4.17) | (5.66) | (3.78) | (1.16) | (0.13) |
| EPS (Diluted) | (4.17) | (5.66) | (3.78) | (1.16) | (0.13) |
| Weighted Avg Shares | 49.41M | 55.03M | 69.31M | 120.96M | 127.23M |
| Weighted Avg Shares (Diluted) | 49.41M | 55.03M | 69.31M | 120.96M | 127.23M |
Arcutis Biotherapeutics, Inc.
NASDAQ:ARQT
Intrinsic Alpha fair value
Locked
Current Price
$27.61
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.